Shop shelves and dealer menus still sell strength like a ladder: 20 per cent, 25 per cent, 30 per cent THC. The implied promise is linear. Twice the number, twice the effect.

A new synthesis of controlled studies says the promise is wrong. Bigger doses do make people feel more intoxicated — but not in proportion. Push the dose up and the extra high shrinks. For occasional users, the curve flattens fast.

That matters in Britain, where most cannabis is still bought without milligram labels, where “strong skunk” is both a public-health scare and a sales pitch, and where first-time users — medical or otherwise — are often guessing from a percentage on a bag.

What the study pooled

Isabella Goodwin at the Australian Catholic University and Amir Englund at King’s College London, with a large international team, published a meta-analysis in *Neuroscience and Biobehavioral Reviews* (summarised for the public in The Conversation on 19 October 2026). They combined 41 randomised, double-blind, placebo-controlled studies and 1,020 healthy volunteers who used cannabis less than twice a week and had fewer than 100 lifetime uses — the group most likely to misread potency and overdo it.

Those studies are the gold-standard end of cannabis research: known doses, placebo controls, and subjective ratings taken while people are actually under the drug. Believing you have taken THC can produce a mild high on its own. The team subtracted placebo effects before comparing doses.

They anchored everything to a Standard THC Unit of 5 mg — the dose researchers have proposed as cannabis’s answer to an alcohol unit or a standard drink. It is not yet on UK packaging. It is a useful ruler.

The number that breaks the marketing story

On a 100-point scale, after placebo is stripped out, 5 mg of THC raised reported “high” by about 34 points. It also raised anxiety by 14, tiredness by 26, and a sense of calm by 5. It lowered contentment by 71 and alertness by 40. Even at a modest dose, the picture is mixed: more intoxicated, less happy, less sharp.

Double the dose to 10 mg and “high” only climbs to about 39 points — a 15 per cent bump, not a doubling. Anxiety, tiredness and alertness at 10 mg did not move further than at 5 mg in this pooled analysis.

That pattern has a name in pharmacology: diminishing returns. Receptors saturate. The brain does not scale pleasure and impairment like a spreadsheet. Goodwin and Englund’s plain-language conclusion is the one harm-reduction workers have been saying for years: start low, go slow. Wait. Then decide whether you need more — because “more” will buy less than you expect.

Why this is not the same as “THC does not matter”

Potency has risen. EU monitoring data and national surveys have tracked higher-THC herbal cannabis for decades. Legal markets often sell concentrates at strengths that would have been unthinkable on a 1990s UK street corner. The study is not an argument that THC is irrelevant. It is an argument that dose response is curved, especially for people who do not use often.

For inexperienced users — including many returning adults and some new medical patients — the risk is not only getting high. It is overshooting: anxiety, paranoia, nausea, a bad night that becomes a story about “cannabis doesn’t agree with me.” Those outcomes are more common when people treat percentage THC like a volume knob turned to maximum.

Englund’s group at King’s has spent years on controlled dosing work. This paper sits next to that tradition: measure carefully, report what people actually feel, and stop pretending that twice the chemical means twice the experience.

Tolerance: when the curve steepens again — in the wrong direction

The review focused on acute effects in infrequent users. Regular use rewrites the deal. THC repeatedly activates CB1 receptors; the brain responds by reducing how many are available. You need more drug to reach the same effect. That is tolerance.

Tolerance does not cancel diminishing returns on a single evening. It means that over weeks and months, “strong” becomes normal, and the same product does less until the dose creeps up. Longitudinal work has linked frequent use of high-potency cannabis to higher risk of dependence and, in vulnerable people, psychosis and other mental health problems. Weakening the endocannabinoid system — which helps regulate mood, stress, sleep and appetite — is not a free lunch.

Britain’s illegal market pushes potency because potency sells. A regulated market could in theory cap strengths and label milligrams. Without that, the consumer logic remains: if 25 per cent did not feel like enough last month, try 30. The biology says the second jump may disappoint on pleasure while still charging full price on harm.

What a UK reader should take from it

Percent THC on flower is a poor guide to how you will feel. It describes the plant, not your dose. How much you smoke, how deeply you inhale, whether you hold the smoke, and what else is in the product all move the needle. Two people on the same “28 per cent” bag can report different highs on the same night.

Edibles punish guesswork even harder. Delayed onset makes “nothing’s happening” dangerous. In this meta-analysis, dose–response curves were clearest for inhaled THC; pooled oral dosing did not show the same straight-line relationship with subjective effects, partly because the underlying trials varied more. That is not a licence to treat edibles as weak. It is a warning that the “double the mg, double the high” mistake shows up in hospital data more often than in lab charts. A homemade brownie is not a Standard THC Unit.

Medical cannabis patients are not exempt from the curve. Private clinics can prescribe with more structure than a street purchase, but titration still matters — especially for people who used heavily in the past and arrive with tolerance, or who barely used at all and feel every milligram.

Policy talk about “super-strength skunk” is half right. High potency is real. The missing half is that more THC per gram does not map one-to-one to harm or to intensity of high in the way headlines suggest. A reform debate that only says “weaken the weed” without teaching dose and delay is incomplete. So is a commercial market that treats THC percentage as the main brand attribute.

Limits, as always

Meta-analyses inherit every mess in the underlying trials. These studies differed in synthetic versus herbal THC, joints versus vapour, doses measured, and settings. Pooling them is powerful for a general pattern; it is not a bespoke prediction for your body on a Friday.

Goodwin and Englund call for direct head-to-head trials in the same volunteers at the doses people actually use. Until then, the pooled message stands: the high rises quickly at low doses, then extra THC adds less and less to intoxication — while still carrying room for unpleasant effects if you pile on too fast.

Cannabis is getting stronger. The way people feel it is not getting simpler. Doubling the THC is not doubling the high. For anyone new, occasional, or coming back after years away, that is the line worth remembering before the second pull, the second gummy, or the second “it’s not working yet.”

Sources

Goodwin et al., “The subjective effects of Δ9-tetrahydrocannabinol: A systematic review and dose-response meta-regression”, *Neuroscience and Biobehavioral Reviews*, vol. 188, 2026 (King’s Pure portal: KCL publication record). Plain-language summary: Goodwin and Englund, “Cannabis is getting stronger, but doubling THC dose doesn’t get you twice as ‘high’”, The Conversation, 19 October 2026. Standard THC Unit (5 mg) as proposed in controlled-use guidance. EMCDDA/Europol joint publication on high-potency cannabis (potency trends).